Ipamorelin vs Sermorelin vs MK-677: GH Secretagogues Compared

Ipamorelin, sermorelin, and MK-677 all aim to do the same thing: nudge your own pituitary gland into making more growth hormone (GH), instead of injecting GH directly. They get there through different doors, carry different evidence, and come with different legal and safety realities. This guide compares the three side by side so you can see what each actually does, what the research supports, and where the hype runs ahead of the data.

What "growth hormone secretagogue" actually means

A secretagogue is anything that triggers a gland to release a hormone it already makes. A growth hormone secretagogue (GHS) tells your pituitary to pulse out more of its own GH. That's the shared idea behind all three compounds here. None of them is growth hormone. They work upstream of it.

This matters for two reasons. First, because the pituitary stays in charge, these compounds tend to preserve the natural pulsing rhythm of GH release and the body's feedback brakes. That's the theoretical safety advantage over injecting recombinant GH, which floods the system with a flat, constant signal. Second, if your pituitary is damaged or absent, a secretagogue has nothing to work with. Whatever GH-raising effect you get depends on a working gland.

The three compounds split into two mechanistic families:

• GHRH analogs copy growth hormone-releasing hormone, the brain signal that tells the pituitary to make GH. Sermorelin is in this family.
• Ghrelin mimetics (GH secretagogue receptor agonists) copy ghrelin, the "hunger hormone," which independently stimulates GH release and amplifies the GHRH signal. Ipamorelin and MK-677 are in this family.

Because the two families act through different receptors, they can be combined for an additive effect. That's the logic behind common stacks like CJC-1295 paired with ipamorelin, which we cover in our CJC-1295 vs ipamorelin comparison.

Why the pulse pattern matters

Your body doesn't release GH in a steady drip. It comes out in bursts, mostly during deep sleep, with very little circulating between bursts. Those troughs are not a flaw; they're part of how the system stays sensitive. When GH is high all the time, receptors downregulate and the body adapts in ways that blunt the response and can cause side effects. That's the core problem with injecting recombinant GH: it overrides the natural rhythm.

The short-acting compounds here, sermorelin and ipamorelin, work with that rhythm. They produce a pulse and then clear out, leaving the troughs intact. MK-677 does the opposite. Its long half-life produces a continuous elevation, which is more convenient and more likely to drive side effects like water retention and insulin resistance. That single difference, pulse versus plateau, explains a lot of why these compounds feel and behave differently in practice.

The three compounds at a glance

Feature	Ipamorelin	Sermorelin	MK-677 (ibutamoren)
Class	Ghrelin mimetic / GHS-R agonist (pentapeptide)	GHRH analog (GHRH 1-29)	Ghrelin mimetic / GHS-R agonist (non-peptide)
Route	Subcutaneous injection	Subcutaneous injection	Oral (tablet/liquid)
Half-life	~2 hours	~10-20 minutes	~24 hours
Dosing rhythm	1-3x daily, pulsatile	Usually nightly, pulsatile	Once daily, sustained
Appetite effect	Minimal	Minimal	Strong increase (common)
Cortisol/prolactin spike	Very low (its selling point)	Low	Low
Water retention	Low	Low	Common, sometimes notable
Human clinical trial data	Very limited	Older, mostly diagnostic/pediatric	Multiple RCTs, largest dataset
FDA-approved drug?	No	Formerly (Geref, discontinued)	No
Legal status (US, 2026)	Research chemical / compounded gray area	Compounded via prescription	Research chemical (not approved)

The single most important row in that table is the last one on trial data. MK-677 has been studied in real randomized controlled trials in humans. Ipamorelin has barely been tested in people. Sermorelin's human data is real but old and mostly about diagnosing GH deficiency, not anti-aging. Keep that asymmetry in mind through the rest of this guide.

Ipamorelin: the "clean" ghrelin mimetic

Mechanism

Ipamorelin is a five-amino-acid peptide that binds the growth hormone secretagogue receptor (GHS-R), the same receptor ghrelin uses. When it was first described, researchers highlighted that it stimulated GH release without meaningfully raising cortisol, prolactin, or adrenocorticotropic hormone (ACTH) at effective doses. That selectivity is the whole reason it became popular. Earlier ghrelin-mimetic peptides like GHRP-6 and GHRP-2 also raise GH, but they tend to spike other hormones and appetite along with it. Ipamorelin was bred to avoid that (Raun et al., 1998).

What the evidence actually shows

This is where honesty matters. The famous selectivity data come from animal and early pharmacology work, not large human trials. There is no robust body of randomized human evidence showing that ipamorelin builds muscle, burns fat, or improves clinical outcomes in healthy adults. Most of what people report comes from anecdote, clinic marketing, and extrapolation from how it moves GH and insulin-like growth factor 1 (IGF-1) in the short term.

Honest grade: mechanistically clean, clinically unproven. Ipamorelin reliably raises GH in the short term. Whether that translates into the body-composition and recovery benefits people want, over months, in humans, has not been established in quality trials. You can search the published literature yourself via this PubMed search for ipamorelin and you'll find how thin the human clinical record is.

Practical profile

• Short half-life means it's typically dosed 1-3 times a day, often before bed and post-workout, to mimic natural GH pulses.
• Side effects are usually mild: injection-site reactions, occasional head rush, water retention.
• Because it's a peptide, it has to be injected; it isn't orally active in any meaningful way.

Sermorelin: the GHRH analog with the longest paper trail

Mechanism

Sermorelin is a synthetic fragment made of the first 29 amino acids of human GHRH, the part that does the work. It binds the GHRH receptor on the pituitary and prompts GH release the same way your own hypothalamus does. Because it works through the normal GHRH pathway, the pituitary's feedback loops stay intact, which is why GHRH analogs are considered physiologically "gentle."

What the evidence actually shows

Sermorelin is the only one of the three that was ever an FDA-approved drug. It was sold as Geref and used mainly as a diagnostic agent to test whether a child's pituitary could respond, and to treat some cases of pediatric GH deficiency. The manufacturer discontinued it years ago, reportedly for business rather than safety reasons. So the human safety record exists, but the trials were built around diagnosis and pediatric deficiency, not adult anti-aging or athletic use.

Honest grade: real human history, narrow original purpose. We know sermorelin can raise GH in people and that it had an acceptable safety profile in its approved uses. We do not have strong modern trials showing it reverses aging, improves body composition, or extends healthspan in otherwise healthy adults. Today it's available almost entirely through compounding pharmacies on prescription, which is a different regulatory situation from an FDA-approved product. You can review the GHRH-analog literature through this PubMed search for sermorelin.

Practical profile

• Very short half-life (minutes), so it's usually injected at night to ride the body's largest natural GH pulse during deep sleep.
• Minimal appetite effect and low risk of cortisol or prolactin disturbance.
• Often combined with a ghrelin mimetic for additive GH release. We break down the GHRH-analog family in our overview of growth hormone peptides: sermorelin, ipamorelin, and CJC-1295.

MK-677 (ibutamoren): the oral one with the most data

Mechanism

MK-677, also called ibutamoren, is not a peptide. It's a small, orally active molecule that mimics ghrelin at the GHS-R. Because it survives digestion and has a roughly 24-hour half-life, one daily tablet produces a sustained rise in GH and IGF-1, rather than a brief pulse. That convenience is its biggest draw and, paradoxically, also a knock against it: a flat, sustained signal departs from the body's natural pulsatile pattern.

What the evidence actually shows

MK-677 has the strongest human dataset of the three, which is still modest by drug-approval standards.

In a randomized, placebo-controlled trial in healthy older adults, oral MK-677 raised GH and IGF-1 to levels seen in healthy young adults and significantly increased fat-free mass over a year, though it did not improve strength or function in that study (Nass et al., 2008). In hip-fracture patients, trials of MK-0677 tested whether boosting GH/IGF-1 would speed functional recovery; results were mixed, with one phase IIb study not meeting its primary functional endpoint (Adunsky et al., 2011; Bach et al., 2004). A broader review of GH secretagogues concluded that while these agents reliably raise GH and IGF-1, evidence for meaningful clinical benefit, and full long-term safety, is still incomplete (Sigalos & Pastuszak, 2018).

Honest grade: best-studied, but still not proven to be worth it. MK-677 clearly moves the lab numbers. It clearly adds lean mass on the scale. What it has not clearly shown is improved strength, function, or hard health outcomes, and it carries real downsides: increased appetite, water retention, and, importantly, reduced insulin sensitivity and higher blood sugar in some people. That last point is the reason MK-677 is not casual.

Practical profile

• Oral, once daily, usually at night.
• Notable appetite increase is common, which some bodybuilders want and most other people don't.
• Water retention, lethargy, and joint aches show up at higher doses.
• Blood-sugar and insulin-sensitivity changes mean anyone with prediabetes, diabetes, or metabolic risk should be cautious and monitored.

Head-to-head: how to actually choose

If your priority is...	Best fit	Why
Avoiding injections	MK-677	Only orally active option
Cleanest hormonal profile	Ipamorelin	Minimal cortisol/prolactin/appetite effect
Longest human safety track record	Sermorelin	Former FDA-approved drug
Most published human trial data	MK-677	Multiple RCTs, including a 1-year study
Avoiding appetite/blood-sugar issues	Ipamorelin or sermorelin	MK-677 raises appetite and can worsen insulin sensitivity
Mimicking natural GH pulses	Sermorelin or ipamorelin	Short half-lives preserve pulsatility

A fair summary: none of the three is a proven anti-aging or muscle-building therapy in healthy adults. They differ mostly in convenience, hormonal "cleanliness," and how much human data exists. MK-677 has the most evidence and the most baggage. Ipamorelin has the cleanest theoretical profile and the least human proof. Sermorelin sits in between, with a real but dated and narrow clinical history.

Combining them, and the CJC-1295 question

Because GHRH analogs and ghrelin mimetics hit different receptors, clinicians often pair one of each for a larger, more synergistic GH pulse. The most common pairing isn't sermorelin plus ipamorelin, though; it's CJC-1295 (a longer-acting GHRH analog) plus ipamorelin. CJC-1295 lasts longer than sermorelin, so it provides a steadier GHRH "tone" while ipamorelin adds the ghrelin-pathway kick. We compare those two directly in our CJC-1295 vs ipamorelin guide, and we cover the body-composition angle in tesamorelin vs CJC-1295 for body composition.

If you're considering any stack, the GHRH-analog (sermorelin, CJC-1295, tesamorelin) plus ghrelin-mimetic (ipamorelin, MK-677) framework is the one to understand. Stacking two ghrelin mimetics together, like ipamorelin plus MK-677, is usually redundant since they compete for the same receptor.

What to realistically expect, and when

People want a timeline. Here's an honest one, built from how the compounds move lab values rather than from promised outcomes, because the outcome data simply isn't strong.

In the first few weeks, the most reliable change is on bloodwork: GH pulses rise, and IGF-1 climbs toward the upper end of the normal range. Many users also report better, deeper sleep early on, especially with nighttime sermorelin or ipamorelin, which fits the GH-and-sleep connection, though sleep reports are subjective and not well-quantified in trials.

Over one to three months, the changes people notice most are softer and harder to measure: recovery between workouts, skin and nail quality, water balance. With MK-677, appetite climbs noticeably and the scale often moves up, partly from real lean mass and partly from water. None of this is the same as proven strength or performance gains.

Past three months is where claims outrun evidence. The Nass trial showed MK-677 added fat-free mass over a year without improving strength or function, which is the cautionary headline for the whole category: lab numbers and scale weight can move while the things you actually care about, like strength, function, and health, may not. Expectations should be set against that, not against marketing.

A practical point on commitment: these aren't quick experiments. Because the proposed benefits are slow and modest, a fair trial is months, not days, and months of an unproven, often unregulated compound is a real cost in money, monitoring, and risk. Going in clear-eyed about that is part of using them responsibly.

Dosing logic, in plain terms

This is general information about how these compounds are typically structured, not a protocol to follow on your own. Actual dosing should come from a clinician.

• Sermorelin is usually injected once nightly because its few-minute half-life is meant to ride the body's largest natural GH pulse during early deep sleep. Eating right before, especially carbohydrates and fat, blunts the GH response, which is why empty-stomach timing matters.
• Ipamorelin is also short-acting and often dosed once to three times daily, frequently at bedtime and after training, again to layer pulses onto natural ones. The same empty-stomach logic applies.
• MK-677 is taken once daily as a tablet or liquid, commonly at night. Because it lasts about 24 hours, timing matters less for the pulse and more for managing side effects; some people take it in the morning to limit nighttime appetite and grogginess.

Across all three, "more is better" is a trap. Pushing IGF-1 above the normal range increases side effects without a clear payoff, which is exactly why monitoring bloodwork beats chasing a dose.

Safety, monitoring, and red flags

All three compounds raise IGF-1, and chronically elevated IGF-1 is the central long-term safety question. IGF-1 is a growth signal, and the theoretical concern is that pushing it for years could feed the growth of existing tumors or other unwanted tissue. No GHS has been shown to cause cancer in humans, but none has the multi-decade safety data to rule it out either. Anyone with active cancer, or a personal history of it, should treat these compounds as off-limits without specialist oversight.

Compound-specific cautions:

• MK-677 is the one to watch for metabolic effects. It can raise fasting glucose and reduce insulin sensitivity. People with diabetes, prediabetes, or strong metabolic risk should avoid it or use it only under close monitoring with periodic fasting glucose and HbA1c checks.
• All three can cause water retention, joint aches, tingling (carpal-tunnel-like symptoms), and elevated IGF-1. These are dose-related and usually reverse when you lower the dose or stop.
• Sourcing risk is real. Because ipamorelin and MK-677 are sold mostly as "research chemicals," product purity and dosing accuracy vary widely. Sermorelin from a licensed compounding pharmacy on a prescription is a more controlled situation. For the broader risk picture, see our guide on peptide therapy side effects and risks.

Sensible monitoring before and during use includes baseline and follow-up IGF-1, fasting glucose, and HbA1c, ideally ordered and read by a clinician who knows your history. Cycling is common practice but not well-studied; see our peptide cycling protocols guide for how people structure on/off periods, with the caveat that the evidence base for any specific schedule is thin.

Legal and regulatory reality (US, 2026)

• Sermorelin can be obtained legally through a prescription filled at a compounding pharmacy. It was once FDA-approved (as Geref) but the branded product was discontinued.
• Ipamorelin and MK-677 are not FDA-approved for any use. They circulate mainly as "research chemicals" labeled "not for human consumption," which puts personal use in a legal and safety gray zone. Compounding status for some GHS peptides has tightened, and the FDA has scrutinized which bulk substances pharmacies may use; see the FDA's human drug compounding Q&A for the current framework.
• None of the three is approved as an anti-aging, athletic-performance, or general "wellness" therapy. Marketing that frames them that way is running ahead of the regulatory and evidence reality.

Independent of legality, all three are banned by the World Anti-Doping Agency and most sports leagues. Competitive athletes should treat them as prohibited.

Who each is realistically for

• The convenience-first user who refuses needles and accepts the appetite and blood-sugar trade-offs gravitates to MK-677, ideally with medical monitoring.
• The "minimal side effects" user who wants the cleanest hormonal profile and is comfortable injecting tends toward ipamorelin, usually stacked with a GHRH analog.
• The "I want a prescription and a pharmacy" user who values a legal, monitored path leans toward sermorelin (or CJC-1295) through a licensed prescriber.

For everyone else, the honest answer is that the evidence doesn't yet support these as reliable tools for healthspan, muscle, or fat loss in healthy people. The clinical case is strongest for diagnosed adult GH deficiency, which is a specific medical diagnosis your doctor makes, not a self-assessed feeling of low energy. Raising GH and IGF-1 in hypogonadal men is documented (Sigalos et al., 2017), but documented lab changes are not the same as documented health benefits. If you want to dig into the oral compound's full research record, start with this PubMed search for MK-677 and growth hormone.

Frequently Asked Questions

Which of the three raises growth hormone the most?

In the short term, the ghrelin mimetics (ipamorelin and MK-677) tend to produce strong GH pulses, and MK-677's long half-life sustains elevated GH and IGF-1 around the clock. Sermorelin produces a shorter, more pulsatile rise. But "more GH" is not automatically "more benefit." MK-677's sustained elevation also drives its downsides, like appetite and blood-sugar effects. The compound that raises GH most is not necessarily the one that's safest or most useful.

Is MK-677 safe to take long term?

The honest answer is we don't know. MK-677 has the most human data of the three, including a year-long trial, but that's still short by the standard needed to rule out long-term harm. The clearest concern is its tendency to raise blood sugar and reduce insulin sensitivity, which makes it risky for anyone with metabolic issues. Chronically elevated IGF-1 from any GHS is a theoretical long-term concern that hasn't been resolved either way.

Can I take sermorelin and ipamorelin together?

Yes, and combining a GHRH analog with a ghrelin mimetic is a common clinical strategy because they hit different receptors and produce an additive GH release. That said, the more popular pairing is CJC-1295 (a longer-acting GHRH analog) with ipamorelin, because CJC-1295 outlasts sermorelin's very short half-life. Combining two ghrelin mimetics, like ipamorelin and MK-677, is generally redundant.

Are any of these FDA-approved?

Only sermorelin was ever FDA-approved, sold as Geref and used mainly for diagnosing and treating pediatric GH deficiency before it was discontinued. It's now available through compounding pharmacies by prescription. Ipamorelin and MK-677 have never been FDA-approved for human use and circulate as research chemicals. None of the three is approved as an anti-aging or performance therapy.

Will these build muscle the way steroids or injected GH do?

No. These compounds nudge your own GH up within a physiologic range; they don't flood the body the way supraphysiologic steroid or GH dosing does. MK-677 has shown gains in lean mass on the scale in trials, but much of that may be water and it did not reliably improve strength. For muscle-building purposes, the GH secretagogue class is a modest, slow, and unproven tool compared with the drugs people often imagine they resemble.

---

This article is for educational purposes only and is not medical advice. Talk to a qualified healthcare provider before starting any peptide, hormone, or supplement, especially if you have a medical condition or take other medications.